The Social Media Show
Gynecologic Oncologist Dr. Mike Janicek explains how removing the ovaries can reduce a woman’s risk of developing breast cancer, and by how much. Women often times avoid removing the ovaries because they don’t want to deal with early menopause. Dr. Janicek explains how this can be avoided. Watch this video to learn more about risk [...]
Adjuvant therapy is treatment that done in addition to surgery. Chemotherapy and anti-hormonal therapy are examples of adjuvant therapy. Dr. Harness explains more about adjuvant therapy in the video below. Jay K. Harness, MD: What is adjuvant therapy? The word adjuvant or “adjunctive to” means therapy that is in addition to the surgery that I [...]
Learn from Dr. Margileth about the appropriate time to switch from aromatase inhibitors to tamoxifen based on toxicity. David A. Margileth, M.D.: There was a trial called the ATAC trial that was reported in 2005 whose findings were that in postmenopausal women in the adjuvant therapy of breast cancer five years of aromatase inhibitor was slightly [...]
Learn about the latest breast cancer research on the benefits of using aromatase inhibitors after completing 5 years of tamoxifen therapy. David A. Margileth, M.D.: There was a trial mainly conducted in Canada called the MA.17 trial where they took postmenopausal patients who had completed five years of tamoxifen and randomized those patients to take no [...]
Dr. Margileth explains the potential benefits of using aromatase inhibitors for longer than 5 years. David A. Margileth, M.D.: When the ATAC trial was reported in 2005 that indicated that the aromatase inhibitors were slightly better than tamoxifen in postmenopausal women, the time that they picked to give the aromatase inhibitors was like tamoxifen for five [...]
Discover how quitting tamoxifen therapy early affects your risk of breast cancer recurrence. David A. Margileth, M.D.: There are now two trials looking at the utility of taking tamoxifen after lumpectomy and possibly radiation therapy for ductal carcinoma in situ. It should be remembered that ductal carcinoma in situ has no potential to spread so that [...]
Dr. Margileth explains the risk-to-benefit ratio for the aromatase inhibitors used in breast cancer treatment. David A. Margileth, M.D.: Anytime we decide to do a treatment or a drug in a patient the basis of that is the benefit versus the risk. In breast cancer, this issue becomes very, very common and especially with the aromatase [...]
In this video, Dr. Margileth outlines the risks and benefits of aromatase inhibitors, such as Arimidex. He explains why they are beneficial for patients and discusses the potential side effects. David A. Margileth, M.D.: Like all treatments for cancer, one has to analyze the benefits of the treatment and the risks and toxicity of the treatment. [...]
Discover how long tamoxifen is typically prescribed after breast cancer surgery. Dr. Margileth explains the research underpinning the treatment duration. David A. Margileth, M.D.: When tamoxifen was first developed in the early 80s it replaced removal of the ovaries as a hormone manipulation for the treatment of breast cancer. The initial trials looked at two years [...]
Learn from Dr. Margileth what metastatic lobular carcinoma is and how it is typically treated. David A. Margileth, M.D.: There are two main pathologic types of breast cancer. With invasive breast cancer, 80% of breast cancer is what is called invasive ductal and about 10% is invasive lobular. Lobular tumors are characterized by a couple of [...]
